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Abstract  Hereditary  angioedema  (HAE),  with  an  estimated  prevalence  of  1:50,000,  is  a  rare
but potentially  fatal  disease.  It  may  present  with  recurrent  systemic  edema  of  the  subcutaneous
tissue and  mucous  membranes.  Patients  with  HAE  are  at  increased  risk  for  clinical  worsening
with surgical  stress,  and  may  develop  respiratory  distress  syndrome  due  to  impaired  airway  and
hemodynamic  instability.  The  perioperative  management  of  these  patients  requires  speciﬁc
interventions.  We  present  a  clinical  case  of  a  woman,  50  years  old,  with  HAE  type  II  scheduled
for ureteral  stent  placement  via  endoscopic  approach.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.
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Considerac¸ões anestésicas  perante  um  doente  com  angioedema  hereditário  --  Caso
clínico
Resumo  O  angioedema  hereditário  (AEH),  com  uma  prevalência  estimada  de  1:50000  pes-
soas, é  uma  doenc¸a  rara  mas  potencialmente  fatal.  Pode  se  apresentar  com  edema  sistêmico
recorrente  do  tecido  subcutâneo  e  das  mucosas.  Os  doentes  com  AEH  têm  um  risco  acrescido
de agudizac¸ão  clínica  com  o  estresse  cirúrgico,  podem  desenvolver  síndromes  de  diﬁculdade
respiratória  por  compromisso  da  via  aérea  e  de  instabilidade  hemodinâmica.  A  abordagem  peri-
operatória  desses  doentes  requer  intervenc¸ões  especíﬁcas.  Apresentamos  um  caso  clínico  de
uma mulher  de  50  anos  com  AEH  tipo  II  indicada  para  realizar  ureteroscopia  com  colocac¸ão  de
stent.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.Please  cite  this  article  in  press  as:  Vilac¸a MJ,  et  al.  Anesthetic
--  A  clinical  case.  Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/
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ntroduction
ereditary  angioedema  (HAE)  is  an  autosomal  dominant  dis-
ase  characterized  by  quantitative  or  qualitative  changes
n  the  level  of  the  ﬁrst  complement  cascade  component
nhibitor  (or  C1  esterase  inhibitor  --  C1-INH),  allowing  uncon-
rolled  activation  of  the  classical  complement  cascade.1,2
AE  classiﬁcation  had  two  variants  phenotypes:  type  I
s  characterized  by  low  plasma  levels  of  normally  func-
ional  C1-INH;  type  II  is  characterized  by  the  presence
f  normal  or  high  plasma  levels  of  C1-INH  nonfunctional
r  abnormally  functional.1 More  recently,  the  existence
f  a  third  type  of  an  estrogen-dependant  HAE  with  nor-
al  functional  and  quantitative  levels  of  C1-INH  has  been
dentiﬁed.3
Despite  its  name,  C1-INH  not  only  acts  on  the
omplement  cascade,  it  also  inhibits  proteases  from  coagu-
ation/ﬁbrinolysis  cascade  and  kinin  pathways.  In  HAE,  the
ssociated  symptoms  are  mainly  due  to  interference  on  kinin
athways  with  increased  bradykinin  production.  Clinically,
AE  may  present  with  systemic  and  recurrent  edema  of  sub-
utaneous  tissue  or  mucous  membrane,  with  involvement  of
he  gastrointestinal  system.  It  can  be  misinterpreted  as  an
cute  abdomen  condition;  airway  condition  with  respiratory
istress,  laryngospasm,  bronchospasm,  and  choking;  hemo-
ynamic  instability  due  to  anaphylactic  shock  and  death.1,4
rauma  is  the  precipitating  factor  of  the  clinical  picture  in
bout  one  third  of  patients.  Other  triggering  factors  are
nfection,  anxiety,  and  estrogens.  In  a  signiﬁcant  number
f  cases,  the  precipitating  factor  is  not  identiﬁed.5,6
ase report
e  describe  the  perioperative  anesthesia  care  to  a  50
ears  old  woman  scheduled  for  urologic  elective  surgery:
reteroscopy  with  stenting  for  non-radiopaque  kidney
tones.  The  patient  had  a  diagnosis  of  HAE  type  II  and  a
ositive  family  history  (father  and  brother  with  the  same
ondition).  She  was  being  followed-up  at  the  hospital  with
mmunoallergology  consultation  and  had  no  regular  therapy.
After  careful  preanesthetic  evaluation,  and  in  accor-
ance  with  the  preoperative  protocol  of  the  immune-
ematology  service  of  our  hospital  and  her  immunoaller-
ology  consultation,  prophylaxis  was  performed  with  four
ral  doses  of  stanozolol  4  mg  (Winstrol®)  two  days  prior  to
urgery  and  administration  of  1000  U  of  C1-INH  concentrate
Berinert®)  45  min  before  surgery,  at  slow  intravenous  bolus.
remedication  with  diazepam  1  mg  was  given  at  the  night
efore  surgery  and  on  the  morning  of  surgery.
On  the  day  of  surgery  and  upon  arrival  in  the  operating
oom,  she  was  monitored  with  standard  monitoring  and  pre-
reated  with  intravenous  midazolam  (2.5  mg).  Subarachnoid
lockade  was  the  anesthetic  technique  of  choice,  performed
ith  a  25G  beveled  needle  at  L3--L4  level  with  bupiva-
aine  0.5%  (15  mg),  with  median  approach  and  a  blockade
p  to  T10.  Parecoxib  (40  mg)  was  administered  and  antibi-Please  cite  this  article  in  press  as:  Vilac¸a MJ,  et  al.  Anesthetic
--  A  clinical  case.  Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/
tic  prophylaxis  performed  with  intravenous  cefoxitin  (2  g).
ccording  to  the  protocol,  500  U  of  C1-INH  concentrate
Berinert®)  were  maintained  on  standby  in  the  operating
oom,  in  the  event  of  an  acute  clinical  picture.
C
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The  surgery  lasted  20  min;  the  patient  remained  hemo-
ynamically  stable  during  surgery  and  in  the  immediate
ostoperative  period.  Postoperative  care  did  not  require
peciﬁcity  associated  with  HAE,  and  the  patient  was  treated
ith  intravenous  paracetamol  and  IV  parecoxib,  antibiotic
nd  ﬂuid  therapy.  The  patient  was  discharged  after  24  h.
iscussion
here  are  numerous  factors  precipitating  acute  exacerba-
ions  of  HAE,  particularly  perioperative  anxiety  and  surgical
rauma,  hence  the  importance  of  an  adequate  premedi-
ation.
The  acute  episode  approach,  with  symptoms  and  varying
everity,  is  controversial.  Evidence-based  medicine  suggests
hat  acute  exacerbations  may  not  respond  to  treatment
ith  epinephrine,  antihistamines,  or  glucocorticoids,  a  more
peciﬁc  therapy  is  required.5,7 The  initial  approach  of  a
evere  acute  episode  should  include  the  use  of  recombinant
1-inhibitor  drugs  or  bradykinin  receptor  antagonists.2,3,6,7
hen  these  drugs  are  not  available,  other  approaches
nclude  the  use  of  higher  doses  of  androgens,  such  as  dana-
ol  or  derivatives,  tranexamic  acid  (TA),  epinephrine  (not
lways  effectively),  analgesic  control,  ﬂuid  therapy,  and
ntensive  supportive  therapy.5,6 The  use  of  fresh  frozen
lasma  remains  controversial  due  to  its  theoretical  potential
o  exacerbate  and  perpetuate  the  shock.6
The  most  appropriate  approach  for  this  pathology  is
he  prophylaxis.5,6 Thus,  in  elective  surgery,  the  approach
hould  include  anxiolytic  premedication  and:
(a)  Use  of  recombinant  factor  C1-INH  in  the  following
dosages:  500  U  (if  <50  kg);  1000  U (if  >50  kg,  but  <100  kg)
or  4000  U  (if  >100  kg)  30--60  min  prior  to  the  surgical  pro-
cedure,  with  daily  repetition  if  the  risk  of  precipitating
an  acute  episode  remains  high.
b)  Androgen  derivatives,  up  to  ﬁve  to  seven  days  before
surgery.
(c)  Eventually  TA,  although  not  as  effective  as  androgen
derivatives.
d)  Double  prophylactic  therapy,  as  was  our  option.
The  regional  anesthesia  technique  option  also  presents
dvantages  over  general  anesthesia,  as  it  does  not  imply  an
irway  active  manipulation  that,  by  triggering  an  episode  of
xacerbation  with  a  more  localized  impact,  could  lead  to  a
aryngeal  edema.
In  conclusion,  HAE  is  a  rare  disease,  with  a  few
ontact  by  most  anesthesiologists.  Due  to  the  potential
or  originating  severe  complications,  it  requires  a  careful
erioperative  preparation,  with  the  involvement  of  multidis-
iplinary  teams  (immuno-hemotherapists,  surgeons,  critical
are  physicians,  immunoallergologists,  and  anesthesiolo-
ists),  adoption  of  an  appropriate  prophylaxis,  and  correct
onitoring  of  the  patient. considerations  for  a  patient  with  hereditary  angioedema
10.1016/j.bjane.2015.03.007
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